A COMPARATIVE STUDY BETWEEN TRABECULECTOMY WITH MITOMYCIN-C VERSUS TRABECULECTOMY WITH OLOGEN FOR PATIENTS WITH PRIMARY ANGLE CLOSURE GLAUCOMA
Ahmed G. Elmahdy*
Introduction: Wound healing and scar formation after trabeculectomy may result in fibrosis of the bleb and obstruction of the drainage fistula, eventually leading to bleb failure. Hence, the inhibition of scar formation during the wound-healing process should promote greater success. Recently, tissue-engineered biodegradable implant (Ologen) has been created as an alternative augmentation in trabeculectomy with much less complications. Purpose: The aim of this study is to compare the result and safety of trabeculectomy with Ologen vs. with MMC in patients with Primary angle closure glaucoma. Patients and methods: 48 eyes of 30 patients were undergone subscleral trabeculectomy; 24 eyes with MMC (control group) and 24 eyes with Ologen (study group) and followed-up for one year. The success is by maintaining IOP equal to or less than 21 mmHg without anti-glaucoma eye drops all over the period of follow-up. Results: There were no significant differences between the groups in terms of age, gender, type of glaucoma and preoperative IOP. Mean IOPs for both groups were significantly lower than preoperative levels at all intervals (P< 0.001). At last visit, the mean postoperative IOP was 15.87±4.1 mmHg in MMC group and 16.17±4.3 mmHg in Ologen group with P-value (P= 0.806). The success rate was 87.5% (21/24) in MMC group and 83.3% (20/24) Ologen group. The incidences of early post-operative complications were similar in the 2 groups. Conclusion: the success of trabeculectomy with Ologen is lower than that achieved by trabeculectomy with MMC but with no statistically significant difference. However, this implant could be a safe and effective alternate to MMC with almost similar long-term success rate.
Keywords: trabeculectomy, Ologen,
[Full Text Article]